Pulmonx (LUNG) to Release Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) is expected to be announcing its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:00 PM ET.

Pulmonx Trading Up 3.5%

Shares of LUNG stock opened at $1.47 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.15 and a current ratio of 4.86. The company has a market capitalization of $60.64 million, a price-to-earnings ratio of -1.04 and a beta of 0.07. Pulmonx has a 52-week low of $1.31 and a 52-week high of $9.37. The company has a 50-day simple moving average of $2.00 and a two-hundred day simple moving average of $1.79.

Analysts Set New Price Targets

LUNG has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a report on Thursday, January 22nd. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Lake Street Capital decreased their target price on Pulmonx from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, October 28th. Finally, D. Boral Capital reissued a “buy” rating and issued a $14.00 price target on shares of Pulmonx in a report on Thursday, November 13th. Five analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $6.81.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP boosted its position in shares of Pulmonx by 34.8% in the third quarter. Susquehanna International Group LLP now owns 67,794 shares of the company’s stock valued at $110,000 after acquiring an additional 17,484 shares during the period. Citadel Advisors LLC lifted its stake in Pulmonx by 213.5% in the 3rd quarter. Citadel Advisors LLC now owns 217,176 shares of the company’s stock worth $352,000 after purchasing an additional 147,904 shares in the last quarter. Algert Global LLC boosted its holdings in Pulmonx by 229.6% in the 3rd quarter. Algert Global LLC now owns 77,722 shares of the company’s stock valued at $126,000 after purchasing an additional 54,142 shares during the period. ADAR1 Capital Management LLC boosted its holdings in Pulmonx by 4.9% in the 3rd quarter. ADAR1 Capital Management LLC now owns 214,497 shares of the company’s stock valued at $347,000 after purchasing an additional 10,000 shares during the period. Finally, Jane Street Group LLC grew its position in shares of Pulmonx by 3,328.7% during the 2nd quarter. Jane Street Group LLC now owns 88,631 shares of the company’s stock valued at $230,000 after purchasing an additional 86,046 shares in the last quarter. Institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.